The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
RAS signaling pathways, mutations and their role in colorectal cancer
Open accessAbstract
Two of the main cellular pathways in which the RAS protein operates are the mitogen-activated protein kinases (MAPK) and phosphoinositide-3 kinase (PI3K) pathways. In a normal cell, these are important in controlling several functions, such as cell growth and survival. It becomes self-evident that these events will be disrupted in a malignant cell with a deregulated MAPK or PI3K pathway. Mutations in genes involved in these pathways and interacting with RAS, as well as RAS itself will be discussed. The second part of this review concentrates on how crucial RAS signaling is in colorectal cancer progression, with references to treatment response and prognosis when RAS or other related mutations are present.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They are also associated with lower response rates to chemotherapy and shorter overall survival in several clinical cohorts [7].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Molecular Genetics of Colorectal Cancer
Fearon, E. R. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130235 · Cited by 1,805
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Cancer Research Communications
Calura, E., Fruscio, R., Paracchini, L., Bignotti, E., Martini, P., Sales, G., Beltrame, L., Clivio, L., Ceppi, L., Di Marino, M., et al. (2021) · doi:10.1158/1078-0432 · Cited by 1,537
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,268
Donninger, H., Vos, M. D., & Clark, G. (2007) · Journal of Cell Science · doi:10.1242/jcs.010389 · Cited by 451
Joseph, E. W., Pratilas, C. A., Poulikakos, P. I., Tadi, M., Wang, W., Taylor, B. S., Halilovic, E., Persaud, Y., Xing, F., Viale, A. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008990107 · Cited by 446
Baldus, S. E., Schaefer, K.-L., Engers, R., Hartleb, D., Stoecklein, N. H., & Gabbert, H. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2446 · Cited by 432
Signaling Interplay in Ras Superfamily Function
Mitin, N., Rossman, K. L., & Der, C. J. (2005) · Current Biology · doi:10.1016/j.cub.2005.07.010 · Cited by 402
Reuter, C. W., Morgan, M. A., & Bergmann, L. (2000) · Blood · doi:10.1182/blood.v96.5.1655 · Cited by 300
New insight into BRAF mutations in cancer
Dhomen, N. S., & Marais, R. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.005 · Cited by 278
Ortiz-Vega, S., Khokhlatchev, A. V., Nedwidek, M., Zhang, X., Dammann, R., Pfeifer, G. P., & Avruch, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205192 · Cited by 209
Heinemann, V., Stintzing, S., Kirchner, T., Boeck, S. H., & Jung, A. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.005 · Cited by 209
Nitti, D., Belluco, C., Montesco, M. C., Bertorelle, R., Pian, P. P. D., Fassina, A., Ninfo, V., Chieco‐Bianchi, L., & Lise, M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10165-4 · Cited by 182
Rizzo, S., Bronte, G., Fanale, D., Corsini, L. R., Silvestris, N., Santini, D., Gulotta, G., Bazan, V., Gebbia, N., Fulfaro, F., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70021-9 · Cited by 165
KRAS and BRAF: drug targets and predictive biomarkers
Vakiani, E., & Solit, D. B. (2010) · The Journal of Pathology · doi:10.1002/path.2796 · Cited by 164
CHOP Enhancement of Gene Transcription by Interactions with Jun/Fos AP-1 Complex Proteins
Ubeda, M., Vallejo, M., & Habener, J. F. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7589 · Cited by 141
HER 2/neu protein expression in colorectal cancer
Schuell, B., Gruenberger, T., Scheithauer, W., Zielinski, C. C., & Wrba, F. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-123 · Cited by 132
Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Yokota, T. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012799014968 · Cited by 127
Gallinger, S., Aronson, M. D., Shayan, K., Ratcliffe, E. M., Gerstle, J. T., Parkin, P. C., Rothenmund, H., Croitoru, M. E., Baumann, E., Durie, P. R., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.008 · Cited by 125
Merchant, N. B., Voskresensky, I. V., Rogers, C. M., LaFleur, B., Dempsey, P. J., Graves‐Deal, R., Revetta, F. L., Foutch, A. C., Rothenberg, M. L., Washington, M. K., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1216 · Cited by 107
Detection of BRAF V600E mutation by pyrosequencing
Tan, Y. H., Liu, Y., Eu, K. W., Ang, P. W., Li, W. Q., Salto‐Tellez, M., Iacopetta, B. J., & Soong, R. (2008) · Pathology · doi:10.1080/00313020801911512 · Cited by 98
Oki, E., Oda, S., Maehara, Y., & Sugimachi, K. (1999) · Oncogene · doi:10.1038/sj.onc.1202583 · Cited by 70
Colorectal cancer and RASSF family—A special emphasis on RASSF1A
Fernandes, M. S., Carneiro, F., Oliveíra, C., & Seruca, R. (2012) · International Journal of Cancer · doi:10.1002/ijc.27696 · Cited by 66
Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer
Asghar, U. S., Hawkes, E. A., & Cunningham, D. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.040 · Cited by 61
RAS Signaling in Colorectal Carcinomas through Alteration of RAS, RAF, NF1, and/or RASSF1A
Ahlquist, T. C., Bottillo, I., Danielsen, S. A., Meling, G. I., Rognum, T. O., Lind, G. E., Dallapiccola, B., & Lothe, R. A. (2008) · Neoplasia · doi:10.1593/neo.08312 · Cited by 57
Ballinger, A., & Anggiansah, C. (2007) · BMJ · doi:10.1136/bmj.39321.527384.be · Cited by 57
An Update on the Biology of RAS/RAF Mutations in Colorectal Cancer
Nandan, M. O., & Yang, V. W. (2011) · Current Colorectal Cancer Reports · doi:10.1007/s11888-011-0086-1 · Cited by 50
NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer
Čaćev, T. (2005) · Gut · doi:10.1136/gut.2004.053348 · Cited by 47
Reuter, C. W., Morgan, M. A., & Bergmann, L. (2000) · Blood · doi:10.1182/blood.v96.5.1655.h8001655_1655_1669 · Cited by 29
Ali, M. A., & Sjöblom, T. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)71162-0 · Cited by 1
Cited by
Sorted by citations
Ülgen, E., Özışık, O., & Sezerman, O. U. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00858 · Cited by 471
Biomarkers in Cancer Detection, Diagnosis, and Prognosis
Das, S., Dey, M. K., Devireddy, R. V., & Gartia, M. R. (2023) · Sensors · doi:10.3390/s24010037 · Cited by 471
RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression
Rezatabar, S., Karimian, A., Rameshknia, V., Parsian, H., Majidinia, M., Kopi, T. A., Bishayee, A., Sadeghinia, A., Yousefi, M., Monirialamdari, M., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28334 · Cited by 343
Hedgehog/GLI Signaling Pathway: Transduction, Regulation, and Implications for Disease
Sigafoos, A. N., Paradise, B. D., & Fernández-Zapico, M. E. (2021) · Cancers · doi:10.3390/cancers13143410 · Cited by 254
Barbagallo, C., Brex, D., Caponnetto, A., Cirnigliaro, M., Scalia, M., Magnano, A., Caltabiano, R., Barbagallo, D., Biondi, A., Cappellani, A., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.009 · Cited by 224
Metadata
- Authors
- Zenonos, K.
- Affiliations
- University of Birmingham (GB)
- Corresponding author
- Zenonos, Kypros
- Venue
- World Journal of Gastrointestinal Oncology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2013
- Volume
- 5
- Issue
- 5
- Pages
- 97
- ISSN
- 1948-5204 (ISSN-L)
- PMC
- PMC3682174
- OpenAlex
- W2080354187
- Cited by
- 156
- References
- 32
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 11 · 2023: 15 · 2022: 27 · 2021: 19 · 2020: 15 · 2019: 13 · 2018: 15 · 2017: 12 · 2016: 4 · 2015: 4 · 2014: 3 · 2013: 1
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- World Journal of Gastrointestinal Oncology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- Ras signaling, colorectal cancer, RAS mutations, MAPK signaling, PI3K signaling, tumor progression, treatment response, prognosis, cell growth and survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
